Remove 2005 Remove Biosimilars Remove Drug Pricing
article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. Patents are often described as the ‘lifeblood’ of pharmaceutical companies.

article thumbnail

Pharma in Brief’s 2023 Year in Review and Trends for 2024

Pharma in Brief

Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. The Guidance was last updated in 2005. mL formulation in Canada”.